The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Abstract
BACKGROUND: The use of androgen-deprivation therapy for prostate cancer has increased substantially over the past 15 years. This treatment is associated with a loss of bone-mineral density, but the risk of fracture after androgen-deprivation therapy has not been well studied. METHODS: We studied the records of 50,613 men who were listed in the linked database of the Surveillance, Epidemiology, and End Results program and Medicare as having received a diagnosis of prostate cancer in the period from 1992 through 1997. The primary outcomes were the occurrence of any fracture and the occurrence of a fracture resulting in hospitalization. Cox proportional-hazards analyses were adjusted for characteristics of the patients and the cancer, other cancer treatment received, and the occurrence of a fracture or the diagnosis of osteoporosis during the 12 months preceding the diagnosis of cancer. RESULTS: Of men surviving at least five years after diagnosis, 19.4 percent of those who received androgen-deprivation therapy had a fracture, as compared with 12.6 percent of those not receiving androgen-deprivation therapy (P<0.001). In the Cox proportional-hazards analyses, adjusted for characteristics of the patient and the tumor, there was a statistically significant relation between the number of doses of gonadotropin-releasing hormone received during the 12 months after diagnosis and the subsequent risk of fracture. CONCLUSIONS: Androgen-deprivation therapy for prostate cancer increases the risk of fracture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,379
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Bone density at various sites for prediction of hip fractures
Cummings, S. R., Browner, W., Cummings, S. R., Black, D. M., Nevitt, M. C., Browner, W., Genant, H. K., Cauley, J., Ensrud, K., Scott, J., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92555-8 · Cited by 2,446
Development of a comorbidity index using physician claims data
Klabunde, C. N., Potosky, A. L., Legler, J. M., & Warren, J. L. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00256-0 · Cited by 1,845
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,714
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
SMITH, M. R., EASTHAM, J., GLEASON, D. M., SHASHA, D., TCHEKMEDYIAN, S., & ZINNER, N. (2003) · Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650
PROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
DANIELL, H. W., DUNN, S. R., FERGUSON, D. W., LOMAS, G., NIAZI, Z., & STRATTE, P. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)68000-7 · Cited by 452
Skeletal Fractures Negatively Correlate With Overall Survival in Men With Prostate Cancer
Oefelein, M. G., Ricchiuti, V., Conrad, W., & Resnick, M. I. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64561-2 · Cited by 347
National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer
Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P., & Carroll, P. R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.981 · Cited by 329
Studying Radiation Therapy Using SEER-Medicare-Linked Data
Virnig, B. A., Warren, J. L., Cooper, G. S., Klabunde, C. N., Schussler, N., & Freeman, J. (2002) · Medical Care · doi:10.1097/00005650-200208001-00007 · Cited by 286
Self-citationBone Loss following Hypogonadism in Men with Prostate Cancer Treated with GnRH Analogs
Mittan, D. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.8.3656 · Cited by 278
Townsend, M. F., Sanders, W. H., Northway, R. O., & Graham, S. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<545::aid-cncr17>3.0.co;2-3 · Cited by 260
Diamond, T. H., Higano, C. S., Smith, M. R., Guise, T. A., & Singer, F. R. (2004) · Cancer · doi:10.1002/cncr.20056 · Cited by 255
Identification of fractures from computerized medicare files
Ray, W. A., Griffin, M. R., Fought, R. L., & Adams, M. L. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90047-q · Cited by 235
Harlan, L. C., Potosky, A., Gilliland, F. D., Hoffman, R., Albertsen, P. C., Hamilton, A. S., Eley, J. W., Stanford, J. L., & Stephenson, R. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1864 · Cited by 192
OEFELEIN, M. G., RICCHUITI, V., CONRAD, W., SEFTEL, A., BODNER, D., GOLDMAN, H., & RESNICK, M. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65661-3 · Cited by 188
Androgen deprivation therapy for prostate cancer results in significant loss of bone density
Wei, J. T., Gross, M., Jaffe, C. A., Gravlin, K., Lahaie, M., Faerber, G. J., & Cooney, K. A. (1999) · Urology · doi:10.1016/s0090-4295(99)00301-5 · Cited by 169
Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate Cancer
ROSS, R. W., & SMALL, E. J. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)65060-4 · Cited by 161
Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer
Meng, M. V., Grossfeld, G. D., Sadetsky, N., Mehta, S. S., Lubeck, D. P., & Carroll, P. R. (2002) · Urology · doi:10.1016/s0090-4295(02)01560-1 · Cited by 156
Information on Radiation Treatment in Patients with Breast Cancer
Du, X. L., Freeman, J. L., & Goodwin, J. S. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00011-6 · Cited by 153
Self-citationOsteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate Cancer
Ross, R. W., & Small, E. J. (2002) · The Journal of Urology · doi:10.1097/00005392-200205000-00003 · Cited by 142
Fracture Risk Following Bilateral Orchiectomy
Melton, L. J., Alothman, K. I., Khosla, S., Achenbach, S. J., Oberg, A. L., & Zincke, H. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000059281.67667.97 · Cited by 136
Agreement of Medicare Claims and Tumor Registry Data for Assessment of Cancer-Related Treatment
Cooper, G. S., Yuan, Ž., Stange, K. C., Dennis, L. K., Amini, S. B., & Rimm, A. A. (2000) · Medical Care · doi:10.1097/00005650-200004000-00008 · Cited by 124
Fowler, F. J., COLLINS, M. M., Corkery, E. W., Elliott, D. B., & Barry, M. J. (2002) · Cancer · doi:10.1002/cncr.10656 · Cited by 110
Osteoporosis during androgen deprivation therapy for prostate cancer
Smith, M. R. (2002) · Urology · doi:10.1016/s0090-4295(02)01579-0 · Cited by 102
Critical evaluation of hormonal therapy for carcinoma of the prostate
Chodak, G. W., Keane, T. E., & Klotz, L. H. (2002) · Urology · doi:10.1016/s0090-4295(02)01677-1 · Cited by 87
Moróte, J., García, E. M., Trilla, E., Esquena, S., Junquera, J. M. A., Encabo, G., & Reventós, J. (2003) · European Urology · doi:10.1016/s0302-2838(03)00379-8 · Cited by 63
Construct Validity of Medicare Chemotherapy Claims
Lamont, E. B., Lauderdale, D. S., Schilsky, R. L., & Christakis, N. A. (2002) · Medical Care · doi:10.1097/00005650-200203000-00004 · Cited by 51
Hormonal therapy for prostate cancer: primum non nocere
MILBANK, A. J., Dreicer, R., & Klein, E. A. (2002) · Urology · doi:10.1016/s0090-4295(02)01867-8 · Cited by 13
Research works printed but not linked: 6
- Huggins C, 1941, Cancer Res, 1, 293
- 10.1111/j.1532-5415.2004.52029.x · doi:10.1111/j.1532-5415.2004.52029.x
- 10.1016/S0090-4295(02)01964-7 · doi:10.1016/s0090-4295(02)01964-7
- Warren JL, 2002, Med Care, 40, 3
- Prostate cancer. In: Fleming ID, Cooper JS, Henson DE, et al., eds. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven,1997:219-22.
- Virnig BA, 2002, Med Care, 40, 49
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083
Metadata
- Authors
- Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-01-13
- Volume
- 352
- Issue
- 2
- Pages
- 154-164
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1997732940
- Cited by
- 1,375
- References
- 32
- FWCI
- 70.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.